Medical Crossfire®: Expert Perspectives in Geographic Atrophy – How Can We Prepare for a New Era of Treatment?
View More
(CME Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
(COPE Credit) Addressing Healthcare Inequities Diabetic Retinal Vascular Disease: How Can We Address Ethnic Disparities within the Clinic?
View More
Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies
View More
(CME Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(COPE Credit) Community Practice Connections™: Restoring the Surface – Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME/CNE Credit) Community Practice Connections™: Restoring the Surface Impact of Preservatives and Novel Formulations in First Line Treatments for Dry Eye Disease
View More
(CME Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Community Practice Connections™: Improving Management of MGD-Associated Dry Eye Disease—A Look to the Future of Treatment
View More
(COPE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
(CME/CNE Credit) Analyzing Novel Tear Stimulating Treatments for Special Populations in Dry Eye Disease
View More
18th Annual Controversies in Modern Eye Care
May 4, 2024
Register Now!
Satellite Symposia at the 2024 ARVO Annual Meeting
Date TBD
Register Now!
(COPE Credit) Community Practice Connection™: Paradigm Shifts in Presbyopia – Understanding Advances in Topical Treatment Innovations
View More
(CME Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
2nd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
May 18-19, 2024
Register Now!
(COPE Credit) Learning About the Lid – Optimizing Recognition, Diagnosis, and Treatment of Demodex Blepharitis & Blepharoptosis
View More
(CME Credit) Virtual Case Studies™ in Cataract Surgery: Selecting Surgical Techniques and Preventing Intra-Operative Complications
View More
(COPE Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
Neurotrophic Keratitis Management: How Early Intervention Can Make a Difference
View More
(CME Credit) Clinical Crossroads: Navigating Neurotrophic Keratitis – The Importance of Avoiding Pitfalls and Ensuring Early Intervention
View More
17th Annual Controversies in Modern Eye Care
View More
(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME
View More
Thyroid Eye Disease: The Masquerading Eye Disorder—A Guide to Collaborative Care and Accurate Diagnosis
View More
(CME Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Multidisciplinary Perspectives on Saving Sight—The Expanding Role of the Optometrist in Retinal Disease Care
View More
(COPE Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
(CME Credit) Community Practice Connections™: Advances in Geographic Atrophy – Optimizing Diagnosis, Monitoring Progression, and Increasing Communication with Transformative Treatment on the Horizon
View More
What’s New in MGD Beyond Heating and Squeezing?
View More
PulseSight Therapeutics launches to advance non-viral gene therapies for severe retinal diseases
February 28th 2024According to the company, its proprietary non-viral gene therapy platform with minimally invasive delivery technology is providing long lasting gene expression and favorable distribution in the retina.
Read More
Study: Treatment developed to dramatically slow progression of blindness-causing retinal diseases
February 24th 2024Researchers have found that the interactive release of anti-inflammatory drugs depend on the level of retinal degeneration. A customized treatment approach is expected to be developed to reduce patients’ inconvenience of having multiple shots.
Read More
Study examines the influence of the cellular environment on vision
February 10th 2024Researchers noted a study by Ruhr-University Bochum researchers provides crucial evidence that the ECM influences visual sensory motor behavior already at the retina level, without intervention of disease and/or experimental manipulation.
Read More
Mapping the specific progressing anatomic features from drusen to type 3 MNV
February 5th 2024Elodie Bousquet, MD, PhD, and international researchers studied type 3 macular neovascularization (T3 MNV) using optical coherence tomography. In 64.5% of 31 eyes with T3 MNV, it developed over soft drusen, showing drusen growth and outer layer thinning before T3 MNV.
Read More
Researcher: Red light myopia therapy can injure retina
February 1st 2024A University of Houston professor found that the excitement over the results of LLR as a treatment option for patients with myopia may have come too soon, before its efficacy was confirmed. One company is taking exception with the study.
Read More
Reginald Sanders, MD, FASRS, named president of the American Society of Retina Specialists
January 30th 2024Sanders is affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group. He is the first African American and the first PRISM-affiliated physician to serve as president of the ASRS.
Read More
FDA approves trial plan and fast tracks Ascidian Therapeutics' ACDN-01 in Stargardt Disease
January 29th 2024ACDN-01 is the first-ever RNA exon editor to enter clinical development and the only clinical-stage therapeutic targeting the genetic cause of Stargardt disease. Ascidian expects to initiate enrollment in Phase 1/2 STELLAR study in the first half of 2024.
Read More
Biosimilars to treat retinal diseases: Successful outcomes, patient satisfaction
January 23rd 2024Two retina specialists participated in an Ophthalmology Times case-based roundtable discussion and shared their experiences using the anti-VEGF biosimilars, ranibizumab-eqrn and ranibizumab-nuna to manage retinal diseases.
Read More